Patient burden and clinical advances associated with postapproval monotherapy cancer drug trials: a retrospective cohort study
ObjectivesAfter regulatory approval, drug companies, public funding agencies and academic researchers often pursue trials aimed at extending the uses of a new drug by testing it in new non-approved indications. Patient burden and clinical impact of such research are not well understood.Design and se...
Main Authors: | Benjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/2/e034306.full |
Similar Items
-
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
by: James Mattina, et al.
Published: (2017-02-01) -
Conclusion on the peer review of the pesticide risk assessment of postapproval data submitted for the active substance thiamethoxam
by: European Food Safety Authority
Published: (2012-03-01) -
Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study
by: Joshua D. Wallach, et al.
Published: (2018-03-01) -
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
by: Joel M. Kremer, et al.
Published: (2021-03-01) -
Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer
by: Sadayuki Kawai, et al.
Published: (2020-04-01)